WO2017152129A3 - Traitement du glaucome et/ou de maladies rétiniennes, et formulations utiles pour ce traitement - Google Patents

Traitement du glaucome et/ou de maladies rétiniennes, et formulations utiles pour ce traitement Download PDF

Info

Publication number
WO2017152129A3
WO2017152129A3 PCT/US2017/020795 US2017020795W WO2017152129A3 WO 2017152129 A3 WO2017152129 A3 WO 2017152129A3 US 2017020795 W US2017020795 W US 2017020795W WO 2017152129 A3 WO2017152129 A3 WO 2017152129A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
glaucoma
treatment
retinal diseases
formulations useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/020795
Other languages
English (en)
Other versions
WO2017152129A2 (fr
Inventor
Sidney L. WEISS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocular Technologies SARL
Original Assignee
Ocular Technologies SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocular Technologies SARL filed Critical Ocular Technologies SARL
Publication of WO2017152129A2 publication Critical patent/WO2017152129A2/fr
Publication of WO2017152129A3 publication Critical patent/WO2017152129A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des formulations destinées à être administrées par voie topique, telles que des formulations ophtalmiques; et des méthodes d'utilisation de telles formulations. Selon certains aspects et modes de réalisation de l'invention, lesdites formulations peuvent comprendre un acide gras ou un lipide à base de polyoxyl, et/ou un alcool polyalcoxylé, et éventuellement des nanomicelles. L'invention concerne également des méthodes de traitement ou de prévention de maladies ou d'affections, telles que des maladies ou affections oculaires.
PCT/US2017/020795 2016-03-03 2017-03-03 Traitement du glaucome et/ou de maladies rétiniennes, et formulations utiles pour ce traitement Ceased WO2017152129A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662303333P 2016-03-03 2016-03-03
US62/303,333 2016-03-03

Publications (2)

Publication Number Publication Date
WO2017152129A2 WO2017152129A2 (fr) 2017-09-08
WO2017152129A3 true WO2017152129A3 (fr) 2018-07-26

Family

ID=59744422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/020795 Ceased WO2017152129A2 (fr) 2016-03-03 2017-03-03 Traitement du glaucome et/ou de maladies rétiniennes, et formulations utiles pour ce traitement

Country Status (1)

Country Link
WO (1) WO2017152129A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014032026A1 (fr) 2012-08-24 2014-02-27 Mitra Ashim K Formulation ophtalmique d'acide gras ou lipidique de polyoxyle, et traitement de pathologies oculaires
PL3373976T3 (pl) 2015-11-10 2024-06-24 Sun Pharmaceutical Industries Limited Preparaty do stosowania miejscowego i ich zastosowanie
MX2018010395A (es) 2016-02-29 2018-11-29 Sun Pharma Global Fze Formulaciones topicas que contienen cliclosporina y usos de las mismas.
WO2020081562A1 (fr) * 2018-10-15 2020-04-23 Ocuphire Pharma, Inc. Méthodes et compositions permettant le traitement du glaucome et d'affections apparentées

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176356A1 (en) * 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
WO2015179527A1 (fr) * 2014-05-23 2015-11-26 Ocular Technologies Sarl Formulations topiques et leurs utilisations
US20150366953A1 (en) * 2013-02-13 2015-12-24 The Research Foundation For The State University Of New York Glaucoma treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176356A1 (en) * 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
US20150366953A1 (en) * 2013-02-13 2015-12-24 The Research Foundation For The State University Of New York Glaucoma treatment
WO2015179527A1 (fr) * 2014-05-23 2015-11-26 Ocular Technologies Sarl Formulations topiques et leurs utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOWELL, GARETH R. ET AL.: "Combinatorial targeting of early pathways profoundly inhibits neurodegeneration in a mouse model of glaucoma", NEUROBIOLOGY OF DISEASE, vol. 71, 2014, pages 44 - 52, XP029067120 *
HOYNG, PHILIP F. J. ET AL.: "Iloprost, a stable prostacyclin analog, reduces intraocular pressure", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 28, no. 3, 1 March 1987 (1987-03-01), pages 470 - 476, XP055506560 *

Also Published As

Publication number Publication date
WO2017152129A2 (fr) 2017-09-08

Similar Documents

Publication Publication Date Title
HK1211867A1 (en) Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
EP4410312A3 (fr) Formulations topiques contenant de la cyclosporine et leurs utilisations
WO2017158366A3 (fr) Dispositif d'administration ophtalmique et compositions médicamenteuses ophtalmiques
HK1231376A1 (zh) 局部制剂及其应用
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
WO2018115097A9 (fr) Composition ophtalmologique pour le traitement du syndrome de l'oeil sec
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
HK1258588A1 (zh) 用於治疗眼科疾病的化合物和制剂
WO2019209955A3 (fr) Traitements de la presbytie
EP4397375A3 (fr) Formulations d'isoxazoline parasiticide et procédés de traitement de blépharite
WO2011151685A8 (fr) N-acétyl-dl-leucine, médicament neuroprotecteur et rétinoprotecteur
EP4279063A3 (fr) Composition pharmaceutique ophtalmique, son procédé de préparation et son application
WO2015023884A3 (fr) Libération retardée de substances destinées à traiter des troubles oculaires
MX2021007709A (es) Composiciones farmacéuticas oftálmicas y procedimientos para el tratamiento de las enfermedades de la superficie ocular.
BR112017007428A2 (pt) composições de éster de ácido graxo e ácidos graxos autocomnizantes e suas utilizações no tratamento de estados da doença
WO2013189606A3 (fr) Thérapie intermittente pour le traitement de la perte de la vision chez des êtres humains ayant un glaucome et d'autres maladies dégénératives de l'œil
AU2017261303A1 (en) Ophthalmic compositions
EA202191684A1 (ru) Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии
EP4364810A3 (fr) Formulations topiques et leurs utilisations
MX2024003580A (es) Metodos de tratamiento de enfermedades inflamatorias oculares.
WO2011076368A3 (fr) Formulation peptidique ophtalmique topique
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
PH12022550003A1 (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
WO2020023094A3 (fr) Traitement de troubles du stockage lysosomal
WO2017129577A8 (fr) Gabapentine ophtalmique pour le traitement d'ulcères cornéens

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17760950

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17760950

Country of ref document: EP

Kind code of ref document: A2